Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The flavonoid luteolin inhibits niacin-induced flush.

Papaliodis D, Boucher W, Kempuraj D, Theoharides TC.

Br J Pharmacol. 2008 Apr;153(7):1382-7. doi: 10.1038/sj.bjp.0707668. Epub 2008 Jan 28.

2.

A quercetin containing supplement reduces niacin-induced flush in humans.

Kalogeromitros D, Makris M, Chliva C, Aggelides X, Kempuraj D, Theoharides TC.

Int J Immunopathol Pharmacol. 2008 Jul-Sep;21(3):509-14.

PMID:
18831918
3.

Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model.

Papaliodis D, Boucher W, Kempuraj D, Michaelian M, Wolfberg A, House M, Theoharides TC.

J Pharmacol Exp Ther. 2008 Dec;327(3):665-72. doi: 10.1124/jpet.108.141333. Epub 2008 Sep 10.

4.

Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush.

Meyers CD, Liu P, Kamanna VS, Kashyap ML.

Atherosclerosis. 2007 Jun;192(2):253-8. Epub 2006 Sep 1.

PMID:
16945375
5.

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.

Morrow JD, Parsons WG 3rd, Roberts LJ 2nd.

Prostaglandins. 1989 Aug;38(2):263-74.

PMID:
2475889
7.

Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.

Dishy V, Liu F, Ebel DL, Atiee GJ, Royalty J, Reilley S, Paolini JF, Wagner JA, Lai E.

J Clin Pharmacol. 2009 Apr;49(4):416-22. doi: 10.1177/0091270009332246. Epub 2009 Feb 26.

PMID:
19246721
8.
9.

Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice.

Inceoglu AB, Clifton HL, Yang J, Hegedus C, Hammock BD, Schaefer S.

J Cardiovasc Pharmacol. 2012 Jul;60(1):70-5. doi: 10.1097/FJC.0b013e3182580a5d.

10.

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, Sisk CM, Mitchel YB.

Cardiol Clin. 2008 Nov;26(4):547-60. Review.

PMID:
19031552
11.

Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing.

Parson HK, Harati H, Cooper D, Vinik AI.

J Diabetes. 2013 Mar;5(1):59-67. doi: 10.1111/j.1753-0407.2012.00216.x.

PMID:
22727040
12.

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.

Morrow JD, Awad JA, Oates JA, Roberts LJ 2nd.

J Invest Dermatol. 1992 May;98(5):812-5.

13.

The effect of aspirin on niacin-induced cutaneous reactions.

Whelan AM, Price SO, Fowler SF, Hainer BL.

J Fam Pract. 1992 Feb;34(2):165-8.

PMID:
1737967
14.

Apple pectin for the reduction of niacin-induced flushing.

Moriarty PM, Backes J, Dutton JA, He J, Ruisinger JF, Schmelzle K.

J Clin Lipidol. 2013 Mar-Apr;7(2):140-6. doi: 10.1016/j.jacl.2012.11.005. Epub 2012 Dec 5.

PMID:
23415433
15.

Niacin, an old drug with new perspectives for the management of dyslipidaemia.

Benhalima K, Muls E.

Acta Clin Belg. 2010 Jan-Feb;65(1):23-8. Review.

PMID:
20373594
16.

More on niacin: no flush, no good.

[No authors listed]

Harv Health Lett. 2007 Jul;32(9):7. No abstract available.

PMID:
17663076
17.

Niacin: its value in raising HDL cholesterol is being questioned.

[No authors listed]

Heart Advis. 2011 Oct;14(10):7. No abstract available.

PMID:
23019714
18.

The mechanism and mitigation of niacin-induced flushing.

Kamanna VS, Ganji SH, Kashyap ML.

Int J Clin Pract. 2009 Sep;63(9):1369-77. doi: 10.1111/j.1742-1241.2009.02099.x. Review.

19.
20.

Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.

Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ.

Am J Cardiovasc Drugs. 2009;9(2):69-79. doi: 10.2165/00129784-200909020-00001.

PMID:
19331435

Supplemental Content

Support Center